• Donate
  • Contact
Canadian Association of Pompe
  • Home
  • About Us
    • Portraits of Pompe
    • Our Partners
    • Newsletter
  • About Pompe
    • Talk Pompe
    • Webinars
  • Blog
  • Links
  • Connections
Select Page
Audentes Therapeutics Update on Pompe and Other Programs

Audentes Therapeutics Update on Pompe and Other Programs

by Brad Crittenden | May 7, 2019 | News

Audentes Therapeutics provides updates on their AAV-based genetic medicine program for serious rare neuromuscular diseases.

Recent Posts

  • Amicus Remains Hopeful about AT-GAA Despite Mixed Results from Phase 3 Study
  • Cheryl Wong Po Foo
  • Spark Therapeutics Has Begun a Phase 1/2 Gene Therapy Study for Late-Onset Pompe Disease
  • Amicus Therapeutics Has Begun the FDA Submission for Their Pompe Drug, AT-GAA
  • New Review Article Highlights Latest Developments in Pompe Disease Research
  • Terms
  • Privacy

Copyright © 2006 - 2021 Canadian Association of Pompe | Developed by PacificByte